NCT06666790RecruitingNot Applicable
DermaSensor Postmarket Surveillance Study
DermaSensor, Inc.4 sites in 1 country396 target enrollmentStarted: October 8, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 396
- Locations
- 4
- Primary Endpoint
- Device Sensitivity
Study Overview
Brief Summary
The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Screening
- Masking
- Single (Investigator)
Masking Description
Investigator unaided (i.e., blinded/masked) assessment followed by aided assessment of each lesion's malignancy risk.
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men or women of any ethnic group aged 40 and older
- •Primary skin lesion suspicious for melanoma
- •Patient is willing and able to read, understand, and sign the informed consent form (ICF)
Exclusion Criteria
- •Lesion is not accessible to the DermaSensor device Handheld Unit and tip (e.g., inside ears, under nails, etc.)
- •Lesion is on areas of psoriasis, eczema, acne, or similar inflammatory skin conditions that may impede appropriate DermaSensor device tip placement on the lesion.
- •Lesion is greater than 15mm in diameter at the widest point.
- •Lesion has a targeted area less than 2.5mm in diameter where the DermaSensor device tip cannot be placed entirely within the border of the targeted area of the lesion.
- •Lesion has no contiguous area of at least 2.5mm due to ulceration, erosion or liquid discharge (e.g., blood).
- •Lesion is covered by a crust or scale, and lesion surface cannot be cleared of crust or scale such that there is a contiguous area of at least 2.5mm of cleared intact skin that is free of any crust, ulceration, erosion or liquid discharge (e.g., blood).
- •Lesion is obstructed by foreign matter that cannot be non-invasively removed (e.g., tattoo, splinter, etc.)
- •Lesion is not completely cleared of (i.e., free of any remaining residue) dermoscopy oils, makeup, sunscreen, other topical solutions or powders, markings, and staining treatments (e.g., iodine).
- •Lesion is located on acral skin (e.g., sole or palms).
- •Lesion is located within 10mm of the eye.
- •Lesion is on or adjacent to scars, areas previously biopsied, or areas subjected to any past surgical intervention.
- •Lesion is located on mucosal surfaces (e.g. genitals, lips).
- •Lesion is located in an area with acute sunburn.
- •Dementia or other neurologic, physical or psychological limitation that would prevent the patient from signing informed consent and/or completing any required follow-up visits
Outcomes
Primary Outcomes
Device Sensitivity
Time Frame: 39 months
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Completed
Not Applicable
Changes in Skin Conductance Measurement as an Endpoint Monitor for Sympathetic BlocksDisorder, Sympathetic NerveNCT02390323Hospital for Special Surgery, New York13
Completed
Not Applicable
Study of Skin and Muscle Parameters Using a Skin SensorSkin WoundsNCT01722929Northwestern University4
Completed
Not Applicable
DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin CancerSkin CancerNCT06690086DermaSensor, Inc.1,028
Completed
Not Applicable
Evaluation of the Sensitivity of a Transdermal Device to Monitor the Sweat Alcohol ConcentrationThe Sweat Alcohol ConcentrationNCT02860195Assistance Publique Hopitaux De Marseille6
Completed
Not Applicable
MaxAn Post Market Surveillance ValidationDeformityFractureTumorDDDNCT01343693Zimmer Biomet119